Articles

Elsevier,

The Lancet HIV, Volume 10, May 2023

Early treatment of HIV is essential for the health of infants living with HIV; this study looks at ways to improve case-finding.
Elsevier,

The Lancet Healthy Longevity, Volume 4, May 2023

This Article supports SDG 3 by comparing epigenetic ageing during untreated HIV infection and during HIV being treated with antiretroviral therapy. They found that epigenetic ageing was accelarated during the former and decelerated during the latter.
Elsevier,

The Lancet Regional Health - Europe, Volume 28, May 2023

This Article supports SDG 3 by evaluating the effects of a behavioural intersectional stigma coping intervention on stigma and care use. They found that the brief intervention did not change stigma manifestations or drug use behaviours but did reduce the impact of stigma as a barrier to care use.
Elsevier,

The Lancet HIV, Volume 10, May 2023

Dolutegravir is the globally recommended first-line therapy for HIV. In this paper researchers assess the effects of dolutegravir roll-out in the country with the highest HIV burden.
Elsevier,

Cell Chemical Biology, Volume 30, 18 May 2023

Richard et al. provide extensive evidence suggesting that treatment with the HIV-1 attachment inhibitor temsavir can have beneficial effects that extend beyond viral neutralization, notably by preventing elimination of uninfected cells and induction of a cytokine burst caused by its soluble viral glycoprotein.
Elsevier,

The Lancet Global Health, Volume 11, May 2023

This study supports SDG 3 by highlighting that coverage of opioid agonist treatment and syringe exchange programmes (which are associated with reducing HIV transmission) are low in most countries and for the majority of people who inject drugs; although coverage is improving, this is insufficient when compared with the indicator targets set out by WHO, UNAIDS, and the UN Office on Drugs and Crime.
Elsevier,

The Lancet HIV, Volume 10, May 2023

This Article supports SDG 3 by analysing follow-up data from over 200 000 people with HIV from 20 cohorts in North America and Europe who had started ART up to 20 years previously, and showing that estimated life expectancy for people with HIV on long-term ART with high CD4 cell counts is only a few years lower than that in the general population, irrespective of when ART was started.
Elsevier,

Heliyon, Volume 9, May 2023

This study assessed the central auditory processing (CAP) function and its electroencephalogram (EEG) in patients with mild cognitive impairment (MCI) and the early stage of Alzheimer's disease (AD) so as to provide a basis for early recognition and intervention of AD.
Elsevier,

Heliyon, Volume 9, May 2023

An insightful paper on the effects that Nordic Walking can have on the cognitive function of patients with mild Alzheimer’s disease.
Elsevier,

eClinicalMedicine, Volume 59, May 2023

In this follow-up study, virological response to and adverse event profile of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was assessed at 240 weeks. >98% of people with HIV who received B/F/TAF maintained an HIV-1 RNA of

Pages